Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carcinoembryonic antigen-derived peptide bound to HLA-A2 (CEA peptide–HLA-A2 complex)
- Target
- CEA peptide–HLA-A2 complex
- Molecular classification
- MHC class I–presented antigenic peptide complex, Tumor-associated antigen epitope, Adaptive immunity target
01
Overview
The Carcinoembryonic antigen peptide presented on HLA-A2 refers to a tumor-associated epitope formed when peptides derived from the carcinoembryonic antigen are processed and presented on the cell surface by the MHC class I molecule HLA-A*02:01. This peptide:MHC complex is recognized by cytotoxic T lymphocytes, making it a target for immunotherapies such as TCR-engineered T cells and cancer vaccines. However, the immunogenicity of native CEA peptides is often low, requiring the design of high-affinity peptide analogs to improve therapeutic outcomes. The major therapeutic challenge is balancing anti-tumor efficacy with off-tumor toxicity, as CEA is also expressed on certain normal tissues.
- Other names
- CEA/HLA-A2 complexCEA691-699–HLA-A2CEA694-702–HLA-A2CEA–HLA-A*0201 complex
02
Mechanism of action
Recognition of the peptide–HLA-A2 complex by cytotoxic T cell receptors, leading to immune cell activation and tumor cell lysis
03
Biological functions
Antigen presentationImmune surveillanceTriggering cytotoxic T lymphocyte response against CEA-expressing tumor cells
04
Disease associations
Cancer (particularly adenocarcinomas and colorectal, lung, breast, and other solid tumors that express CEA)
05
Safety considerations
On-target, off-tumor toxicity, as normal tissues (especially gastrointestinal epithelium) may express CEA and present CEA peptides, leading to adverse effects such as colitisVariable immunogenicity of different CEA peptides (some have weak binding to HLA-A2, limiting efficacy)Potential for immune escape if tumors downregulate HLA-A2 expression
06
Interacting drugs
Genetically engineered T cell therapies (e.g., TCR-T and CAR-T targeting CEA peptide–HLA-A2)
1 more in the full profile.
07
Biomarkers
Presence of CEA peptide–HLA-A2 on tumor cells (HLA typing and CEA expression serve as biomarkers for therapy selection)Serum CEA protein (for tumor burden monitoring, though not specific to peptide presentation)
Beyond the preview
Go deeper on Carcinoembryonic antigen-derived peptide bound to HLA-A2 (CEA peptide–HLA-A2 complex).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carcinoembryonic antigen-derived peptide bound to HLA-A2 (CEA peptide–HLA-A2 complex).